The results for the two biomarkers used to assess cardiac ischemia—H-FABP and high-sensitivity cardiac troponin (hs-cTnI)—show significant amelioration from phase I to phase II, as well as noteworthy differences depending on the two studied comorbidities. The gene discussed is TNNI3; the disease is myocardial ischemia.